Eye injection safety check: could common treatment raise heart risk?

NCT ID NCT07550777

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether repeated eye injections of bevacizumab, a drug used for diabetic eye disease and other conditions, might affect heart health. Researchers will measure certain enzymes in the blood that are linked to heart disease risk. The study includes 180 adults aged 55 and older who have had at least two injections, plus a healthy comparison group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
bevacizumab (eye injection)
What this could lead to
If successful, this study could help doctors understand whether repeated bevacizumab eye injections raise the risk of heart problems, leading to safer treatment plans.
What could go wrong
This is an observational study, not a treatment trial. It only measures blood markers, not actual heart events, so it cannot prove cause and effect. Results may not change practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGE MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ataturk University Research Hospital, Department of Ophthalmology

    RECRUITING

    Erzurum, Erzurum, 25240, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.